Lopinavir/ritonavir in the treatment of HIV-1 infection

A review

Ashish Chandwani, Jonathan Shuter

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Lopinavir/ritonavir is the first and only coformulated HIV-1 protease inhibitor (PI). Large clinical trials have demonstrated lopinavir/ ritonavir's clinical efficacy in both antiretroviral-naïve and -experienced patients. The immunologic and virologic benefits of treatment with this agent have been proven in HIV-infected adults, adolescents, and children. Smaller studies support the use of lopinavir/ ritonavir monotherapy as a therapeutic option in certain patients. The drug is characterized by a high genetic barrier to resistance, and appears to be more forgiving of non-adherence than earlier, unboosted PIs. The most frequent side effects observed are diarrhea, nausea, and vomiting. These gastrointestinal adverse effects are generally mild to moderate. Metabolic derangements, including hyperlipidemia and glucose intolerance, have also been observed in lopinavir/ritonavir recipients. As the menu of available antiretroviral agents continues to expand, lopinavir/ritonavir remains a proven and effective drug for the treatment of HIV infection.

Original languageEnglish (US)
Pages (from-to)1023-1033
Number of pages11
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number5
StatePublished - 2008

Fingerprint

Lopinavir
Ritonavir
HIV Infections
HIV-1
drug
tolerance
Glucose
recipient
adolescent
Anti-Retroviral Agents
HIV Protease Inhibitors
Therapeutics
Glucose Intolerance
Hyperlipidemias
Protease Inhibitors
Pharmaceutical Preparations
Nausea
Vomiting
Diarrhea
Clinical Trials

Keywords

  • Antiretroviral
  • HIV
  • Kaletra®
  • Lopinavir/ritonavir
  • Protease inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Lopinavir/ritonavir in the treatment of HIV-1 infection : A review. / Chandwani, Ashish; Shuter, Jonathan.

In: Therapeutics and Clinical Risk Management, Vol. 4, No. 5, 2008, p. 1023-1033.

Research output: Contribution to journalArticle

@article{671adf34498c49178a362456db1eddc5,
title = "Lopinavir/ritonavir in the treatment of HIV-1 infection: A review",
abstract = "Lopinavir/ritonavir is the first and only coformulated HIV-1 protease inhibitor (PI). Large clinical trials have demonstrated lopinavir/ ritonavir's clinical efficacy in both antiretroviral-na{\"i}ve and -experienced patients. The immunologic and virologic benefits of treatment with this agent have been proven in HIV-infected adults, adolescents, and children. Smaller studies support the use of lopinavir/ ritonavir monotherapy as a therapeutic option in certain patients. The drug is characterized by a high genetic barrier to resistance, and appears to be more forgiving of non-adherence than earlier, unboosted PIs. The most frequent side effects observed are diarrhea, nausea, and vomiting. These gastrointestinal adverse effects are generally mild to moderate. Metabolic derangements, including hyperlipidemia and glucose intolerance, have also been observed in lopinavir/ritonavir recipients. As the menu of available antiretroviral agents continues to expand, lopinavir/ritonavir remains a proven and effective drug for the treatment of HIV infection.",
keywords = "Antiretroviral, HIV, Kaletra{\circledR}, Lopinavir/ritonavir, Protease inhibitor",
author = "Ashish Chandwani and Jonathan Shuter",
year = "2008",
language = "English (US)",
volume = "4",
pages = "1023--1033",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "5",

}

TY - JOUR

T1 - Lopinavir/ritonavir in the treatment of HIV-1 infection

T2 - A review

AU - Chandwani, Ashish

AU - Shuter, Jonathan

PY - 2008

Y1 - 2008

N2 - Lopinavir/ritonavir is the first and only coformulated HIV-1 protease inhibitor (PI). Large clinical trials have demonstrated lopinavir/ ritonavir's clinical efficacy in both antiretroviral-naïve and -experienced patients. The immunologic and virologic benefits of treatment with this agent have been proven in HIV-infected adults, adolescents, and children. Smaller studies support the use of lopinavir/ ritonavir monotherapy as a therapeutic option in certain patients. The drug is characterized by a high genetic barrier to resistance, and appears to be more forgiving of non-adherence than earlier, unboosted PIs. The most frequent side effects observed are diarrhea, nausea, and vomiting. These gastrointestinal adverse effects are generally mild to moderate. Metabolic derangements, including hyperlipidemia and glucose intolerance, have also been observed in lopinavir/ritonavir recipients. As the menu of available antiretroviral agents continues to expand, lopinavir/ritonavir remains a proven and effective drug for the treatment of HIV infection.

AB - Lopinavir/ritonavir is the first and only coformulated HIV-1 protease inhibitor (PI). Large clinical trials have demonstrated lopinavir/ ritonavir's clinical efficacy in both antiretroviral-naïve and -experienced patients. The immunologic and virologic benefits of treatment with this agent have been proven in HIV-infected adults, adolescents, and children. Smaller studies support the use of lopinavir/ ritonavir monotherapy as a therapeutic option in certain patients. The drug is characterized by a high genetic barrier to resistance, and appears to be more forgiving of non-adherence than earlier, unboosted PIs. The most frequent side effects observed are diarrhea, nausea, and vomiting. These gastrointestinal adverse effects are generally mild to moderate. Metabolic derangements, including hyperlipidemia and glucose intolerance, have also been observed in lopinavir/ritonavir recipients. As the menu of available antiretroviral agents continues to expand, lopinavir/ritonavir remains a proven and effective drug for the treatment of HIV infection.

KW - Antiretroviral

KW - HIV

KW - Kaletra®

KW - Lopinavir/ritonavir

KW - Protease inhibitor

UR - http://www.scopus.com/inward/record.url?scp=56749117743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749117743&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 1023

EP - 1033

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 5

ER -